EGFR and cancer: The insight that would eventually become sotorasib and adagrasib took advantage of the rise—or rerise—of covalent molecules as human drugs.6 The (re)discovery of the uses of covalency has allowed for overcoming resistance and developing more selective cancer drugs in other settings, such as Bruton’s tyrosine kinase (BTK) inhibitors or the ­3rd-generation epidermal growth factor receptor (EGFR) TKI, osimertinib.